Why Novavax (NVAX) is a Top Momentum Stock for the Long-Term

Novavax (NVAX), a biotechnology firm, is identified by Zacks as a top momentum stock, holding an 'A' Momentum Style Score and 'A' VGM Score despite its #3 (Hold) Zacks Rank. The company's shares have gained 10.7% over the last four weeks, bolstered by two upward revisions to its fiscal 2025 earnings estimate to $2.66 per share, and a historical average earnings surprise of +335.8%. These factors position NVAX as a potential short-list candidate for investors focused on momentum.

Analysis

Novavax (NVAX) is exhibiting strong momentum signals despite its neutral Zacks #3 (Hold) rating. The company's stock has registered a 10.7% gain over the past four weeks, a performance that aligns with its top-tier 'A' Momentum Style Score. This price action is further supported by positive revisions in analyst sentiment; two analysts have recently revised fiscal 2025 earnings estimates upwards, leading to a marginal increase in the consensus estimate to $2.66 per share. While the 'Hold' rank suggests a more cautious overall outlook, the combination of an 'A' grade for its composite VGM Score and a historical average earnings surprise of an exceptional +335.8% indicates a pattern of outperformance and positive underlying trends that are attractive from a quantitative momentum perspective.

Key Decisions for Investors

• Momentum-focused investors should consider NVAX for their watchlists, as the combination of its 'A' Momentum score, recent price performance, and upward earnings revisions presents a compelling technical setup.
• Investors should weigh the strong momentum indicators against the neutral Zacks #3 (Hold) rank, which could imply that underlying fundamental or valuation concerns are tempering the more bullish quantitative signals.
• Monitor for any further upward revisions to the fiscal 2025 consensus earnings estimate of $2.66, as continued positive analyst actions would be a key confirmation of the current momentum thesis.